SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol. 2004; 22: 330353.
  • 2
    Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 20952103.
  • 3
    Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 4
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 15891597.
  • 5
    Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). Proc Am Soc Clin Oncol. 2004; 23: 622.
  • 6
    Pectasides D, Farmakis D, Pectasides M, et al. Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial. Proc Am Soc Clin Oncol. 2004; 23: 621.
  • 7
    Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study. Clin Cancer Res. 2001; 7: 6873.
  • 8
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1998; 10: 1110.
  • 9
    Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 12811288.
  • 10
    Rothenberg ML. CPT-11: An original spectrum of clinical activity. Semin Oncol. 1996; 23( Suppl 3): S21S26.
  • 11
    Masuda N, Fukuoka M, Fujita A, et al, for CPT-11 Lung Cancer Study Group. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 1998; 78: 251256.
  • 12
    DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999; 17: 27102720.
  • 13
    Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study. Lung Cancer. 2003; 39: 201207.
  • 14
    Han J-Y, Lim H-S, Lee DH, et al. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006; 106: 873880.
  • 15
    CPT-11 Cooperative Study Group. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother. 1991; 18: 10131019.
  • 16
    Nakai H, Fukoka M, Furuse K, et al. An early phase II study of CPT-11 in primary lung cancer. Gam To Kagaku Ryoho. 1991; 18: 607612.
  • 17
    Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. JClin Oncol. 1998; 16: 38583865.
  • 18
    Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer. 2005; 93: 763769.